nach oben

Translational Stroke Research

Erschienen in:

01.02.2016 | Original Article

Partial MHC Constructs Treat Thromboembolic Ischemic Stroke Characterized by Early Immune Expansion

verfasst von: Abby L. Dotson, Yingxin Chen, Wenbin Zhu, Nicole Libal, Nabil J. Alkayed, Halina Offner

Erschienen in: Translational Stroke Research | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Inflammation and thrombosis are tightly linked, with inflammation contributing to thromboembolism and to stroke outcome. Thromboembolism is a frequent cause of ischemic stroke; yet, the most used occlusion mouse models of experimental stroke do not effectively replicate thromboembolism. Our group recently described a novel thromboembolic mouse model of stroke that successfully occludes the middle cerebral artery with high reproducibility. In the current study, we characterize the peripheral and local immune outcomes as well as the ischemic response to immune therapy in a clinically relevant mouse model of thromboembolic stroke. Brain and spleen tissues were harvested 24 h after thromboembolic stroke and cells immunophenotyped by flow cytometry. We observed a significant increase in neutrophils and early activated T cells in the spleen and an increase in neutrophils and activated monocytes/microglia in the ischemic cortex after thromboembolic stroke. Moreover, as was shown previously for transient MCAO models, treatment of thromboembolic stroke with partial MHC constructs significantly reduced ischemic damage indicating an equivalent effect of this immune-based therapy in the thromboembolic model that better mimics the pathophysiology of human stroke.

Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29–e322. doi:10.1161/cir.0000000000000152.CrossRefPubMed

Casals NCP JB, Matheus LT F, Anna CM E, Kelly CS R, Rodrigo SN B, Bressan DSM FF, et al. The use of animal models for stroke research: a review. Comp Med. 2011;61(4):305–13.

Marco Bacigaluppi GCaDMH. Animal Models of Ischemic Stroke: Part Two, Modeling Cerebral Ischemia. Open Neurol J. 2010;4:34–8.

Zhang BJ, Men XJ, Lu ZQ, Li HY, Qiu W, Hu XQ. Splenectomy protects experimental rats from cerebral damage after stroke due to anti-inflammatory effects. Chin Med J (Engl). 2013;126(12):2354–60.

Zhang F, Guo RM, Yang M, Wen XH, Shen J. A stable focal cerebral ischemia injury model in adult mice: assessment using 7T MR imaging. AJNR Am J Neuroradiol. 2012;33(5):935–9. doi:10.3174/ajnr.A2887.CrossRefPubMed

Casals JB, Pieri NC, Feitosa ML, Ercolin AC, Roballo KC, Barreto RS, et al. The use of animal models for stroke research: a review. Comp Med. 2011;61(4):305–13.PubMedCentralPubMed

Offner H, Subramanian S, Parker SM, Afentoulis ME, Vandenbark AA, Hurn PD. Experimental stroke induces massive, rapid activation of the peripheral immune system. J Cereb Blood Flow Metab. 2006;26(5):654–65. doi:10.1038/sj.jcbfm.9600217.CrossRefPubMed

Offner H, Subramanian S, Parker SM, Wang C, Afentoulis ME, Lewis A, et al. Splenic atrophy in experimental stroke is accompanied by increased regulatory T cells and circulating macrophages. J Immunol. 2006;176(11):6523–31.CrossRefPubMed

Seifert HA, Hall AA, Chapman CB, Collier LA, Willing AE, Pennypacker KR. A transient decrease in spleen size following stroke corresponds to splenocyte release into systemic circulation. J Neuroimmune Pharmacol. 2012;7(4):1017–24. doi:10.1007/s11481-012-9406-8.PubMedCentralCrossRefPubMed

10.

Seifert HA, Leonardo CC, Hall AA, Rowe DD, Collier LA, Benkovic SA, et al. The spleen contributes to stroke induced neurodegeneration through interferon gamma signaling. Metab Brain Dis. 2012;27(2):131–41. doi:10.1007/s11011-012-9283-0.CrossRefPubMed

11.

Dotson AL, Wang J, Saugstad J, Murphy SJ, Offner H. Splenectomy reduces infarct volume and neuroinflammation in male but not female mice in experimental stroke. J Neuroimmunol. 2015;278:289–98. doi:10.1016/j.jneuroim.2014.11.020.CrossRefPubMed

12.

Ostrowski RP, Schulte RW, Nie Y, Ling T, Lee T, Manaenko A, et al. Acute splenic irradiation reduces brain injury in the rat focal ischemic stroke model. Transl Stroke Res. 2012;3(4):473–81. doi:10.1007/s12975-012-0206-5.PubMedCentralCrossRefPubMed

13.

Mena H, Cadavid D, Rushing EJ. Human cerebral infarct: a proposed histopathologic classification based on 137 cases. Acta Neuropathol. 2004;108(6):524–30. doi:10.1007/s00401-004-0918-z.CrossRefPubMed

14.

Segel GB, Halterman MW, Lichtman MA. The paradox of the neutrophil’s role in tissue injury. J Leukoc Biol. 2011;89(3):359–72. doi:10.1189/jlb.0910538.CrossRefPubMed

15.

Shichita T, Sugiyama Y, Ooboshi H, Sugimori H, Nakagawa R, Takada I, et al. Pivotal role of cerebral interleukin-17-producing gammadeltaT cells in the delayed phase of ischemic brain injury. Nat Med. 2009;15(8):946–50. doi:10.1038/nm.1999.CrossRefPubMed

16.

Gronberg NV, Johansen FF, Kristiansen U, Hasseldam H. Leukocyte infiltration in experimental stroke. J Neuroinflammation. 2013;10:115. doi:10.1186/1742-2094-10-115.PubMedCentralCrossRefPubMed

17.

Jin R, Yang G, Li G. Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. J Leukoc Biol. 2010;87(5):779–89. doi:10.1189/jlb.1109766.PubMedCentralCrossRefPubMed

18.

Canazza A, Minati L, Boffano C, Parati E, Binks S. Experimental models of brain ischemia: a review of techniques, magnetic resonance imaging, and investigational cell-based therapies. Front Neurol. 2014;5:19. doi:10.3389/fneur.2014.00019.PubMedCentralPubMed

19.

Howells DW, Porritt MJ, Rewell SS, O’Collins V, Sena ES, van der Worp HB, et al. Different strokes for different folks: the rich diversity of animal models of focal cerebral ischemia. J Cereb Blood Flow Metab. 2010;30(8):1412–31. doi:10.1038/jcbfm.2010.66.PubMedCentralCrossRefPubMed

20.

Chen Y, Zhu W, Zhang W, Libal N, Murphy SJ, Offner H, et al. A novel mouse model of thromboembolic stroke. J Neurosci Methods. 2015. doi:10.1016/j.jneumeth.2015.09.013.

21.

Akiyoshi K, Dziennis S, Palmateer J, Ren X, Vandenbark AA, Offner H, et al. Recombinant T cell receptor ligands improve outcome after experimental cerebral ischemia. Transl Stroke Res. 2011;2(3):404–10. doi:10.1007/s12975-011-0085-1.PubMedCentralCrossRefPubMed

22.

Zhu W, Libal NL, Casper A, Bodhankar S, Offner H, Alkayed NJ. Recombinant T cell receptor ligand treatment improves neurological outcome in the presence of tissue plasminogen activator in experimental ischemic stroke. Transl Stroke Res. 2014;5(5):612–7. doi:10.1007/s12975-014-0348-8.PubMedCentralCrossRefPubMed

23.

Vandenbark AA, Rich CMJ, Zamora AWC, Huan J, Fugger L, Offner H, et al. Recombinant TCR ligand induces tolerance to myelin oligodendrocyte glycoprotein 35–55 peptide and reverses clinical and histological signs of chronic experimental autoimmune encephalomyelitis in HLA-DR2 transgenic mice. J Immunol. 2003;171(1):127–33.CrossRefPubMed

24.

Hurn PD, Subramanian S, Parker SM, Afentoulis ME, Kaler LJ, Vandenbark AA, et al. T- and B-cell-deficient mice with experimental stroke have reduced lesion size and inflammation. J Cereb Blood Flow Metab. 2007;27(11):1798–805. doi:10.1038/sj.jcbfm.9600482.PubMedCentralCrossRefPubMed

25.

Bodhankar S, Chen Y, Vandenbark AA, Murphy SJ, Offner H. Treatment of experimental stroke with IL-10-producing B-cells reduces infarct size and peripheral and CNS inflammation in wild-type B-cell-sufficient mice. Metab Brain Dis. 2014;29(1):59–73. doi:10.1007/s11011-013-9474-3.PubMedCentralCrossRefPubMed

26.

Burrows G. JWChang, HPBächinger, DNBourdette, HOffner, Vandenbark A. Design, engineering and production of functional single-chain T cell receptor ligands. Protein Eng. 1999;12(9):771–8.CrossRefPubMed

27.

Dotson AL, Zhu W, Libal N, Alkayed NJ, Offner H. Different immunological mechanisms govern protection from experimental stroke in young and older mice with recombinant TCR ligand therapy. Front Cell Neurosci. 2014;8:284. doi:10.3389/fncel.2014.00284.PubMedCentralCrossRefPubMed

28.

Hossmann KA. The two pathophysiologies of focal brain ischemia: implications for translational stroke research. J Cereb Blood Flow Metab. 2012;32(7):1310–6. doi:10.1038/jcbfm.2011.186.PubMedCentralCrossRefPubMed

29.

Wang YM, Alexander SI. CD8 regulatory T cells: what’s old is now new. Immunol Cell Biol. 2009;87(3):192–3. doi:10.1038/icb.2009.8.CrossRefPubMed

30.

Kleinschnitz C, Kraft P, Dreykluft A, Hagedorn I, Gobel K, Schuhmann MK, et al. Regulatory T cells are strong promoters of acute ischemic stroke in mice by inducing dysfunction of the cerebral microvasculature. Blood. 2013;121(4):679–91. doi:10.1182/blood-2012-04-426734.PubMedCentralCrossRefPubMed

31.

Schabitz WR. Regulatory T, cells in ischemic stroke: helpful or hazardous? Stroke. 2013;44(8), e84. doi:10.1161/STROKEAHA.113.002228.CrossRefPubMed

32.

Stubbe T, Ebner F, Richter D, Engel O, Klehmet J, Royl G, et al. Regulatory T cells accumulate and proliferate in the ischemic hemisphere for up to 30 days after MCAO. J Cereb Blood Flow Metab. 2013;33(1):37–47. doi:10.1038/jcbfm.2012.128.PubMedCentralCrossRefPubMed

33.

Bodhankar S, Chen Y, Lapato A, Vandenbark AA, Murphy SJ, Saugstad JA, et al. Regulatory CD8(+)CD122 (+) T-cells predominate in CNS after treatment of experimental stroke in male mice with IL-10-secreting B-cells. Metab Brain Dis. 2015;30(4):911–24. doi:10.1007/s11011-014-9639-8.CrossRefPubMed

34.

Bodhankar S, Chen Y, Vandenbark AA, Murphy SJ, Offner H. IL-10-producing B-cells limit CNS inflammation and infarct volume in experimental stroke. Metab Brain Dis. 2013;28(3):375–86. doi:10.1007/s11011-013-9413-3.PubMedCentralCrossRefPubMed

35.

Stevens SL, Bao J, Hollis J, Lessov NS, Clark WM, Stenzel-Poore MP. The use of flow cytometry to evaluate temporal changes in inflammatory cells following focal cerebral ischemia in mice. Brain Res. 2002;932(1–2):110–9.CrossRefPubMed

36.

Tokgoz S, Kayrak M, Akpinar Z, Seyithanoglu A, Guney F, Yuruten B. Neutrophil lymphocyte ratio as a predictor of stroke. J Stroke Cerebrovasc Dis. 2013;22(7):1169–74. doi:10.1016/j.jstrokecerebrovasdis.2013.01.011.CrossRefPubMed

37.

Burrows GG, Chou YK, Wang C, Chang JW, Finn TP, Culbertson NE, et al. Rudimentary TCR signaling triggers default IL-10 secretion by human Th1 cells. J Immunol. 2001;167(8):4386–95.CrossRefPubMed

38.

Wang C, Mooney JL, Meza-Romero R, Chou YK, Huan J, Vandenbark AA, et al. Recombinant TCR ligand induces early TCR signaling and a unique pattern of downstream activation. J Immunol. 2003;171(4):1934–40.CrossRefPubMed

39.

Burrows GG, Bebo Jr BF, Adlard KL, Vandenbark AA, Offner H. Two-domain MHC class II molecules form stable complexes with myelin basic protein 69–89 peptide that detect and inhibit rat encephalitogenic T cells and treat experimental autoimmune encephalomyelitis. J Immunol. 1998;161(11):5987–96.PubMed

40.

Huan J, Subramanian S, Jones R, Rich C, Link J, Mooney J, et al. Monomeric recombinant TCR ligand reduces relapse rate and severity of experimental autoimmune encephalomyelitis in SJL/J mice through cytokine switch. J Immunol. 2004;172(7):4556–66.CrossRefPubMed

41.

Subramanian S, Zhang B, Kosaka Y, Burrows GG, Grafe MR, Vandenbark AA, et al. Recombinant T cell receptor ligand treats experimental stroke. Stroke. 2009;40(7):2539–45. doi:10.1161/strokeaha.108.543991.PubMedCentralCrossRefPubMed

42.

Dziennis S, Mader S, Akiyoshi K, Ren X, Ayala P, Burrows GG, et al. Therapy with recombinant T-cell receptor ligand reduces infarct size and infiltrating inflammatory cells in brain after middle cerebral artery occlusion in mice. Metab Brain Dis. 2011;26(2):123–33. doi:10.1007/s11011-011-9241-2.PubMedCentralCrossRefPubMed

43.

Benedek G, Zhu W, Libal N, Casper A, Yu X, Meza-Romero R, et al. A novel HLA-DRalpha1-MOG-35-55 construct treats experimental stroke. Metab Brain Dis. 2014;29(1):37–45. doi:10.1007/s11011-013-9440-0.PubMedCentralCrossRefPubMed

44.

Offner H, Sinha S, Burrows GG, Ferro AJ, Vandenbark AA. RTL therapy for multiple sclerosis: a phase I clinical study. J Neuroimmunol. 2011;231(1–2):7–14. doi:10.1016/j.jneuroim.2010.09.013.PubMedCentralCrossRefPubMed

45.

Pan J, Palmateer J, Schallert T, Hart M, Pandya A, Vandenbark AA, et al. Novel humanized recombinant T cell receptor ligands protect the female brain after experimental stroke. Transl Stroke Res. 2014;5(5):577–85. doi:10.1007/s12975-014-0345-y.PubMedCentralCrossRefPubMed

46.

Zhu W, Dotson AL, Libal NL, Lapato AS, Bodhankar S, Offner H, et al. Recombinant T-cell receptor ligand RTL1000 limits inflammation and decreases infarct size after experimental ischemic stroke in middle-aged mice. Neuroscience. 2015;288:112–9. doi:10.1016/j.neuroscience.2014.12.037.CrossRefPubMed

Titel: Partial MHC Constructs Treat Thromboembolic Ischemic Stroke Characterized by Early Immune Expansion
verfasst von: Abby L. Dotson
Yingxin Chen
Wenbin Zhu
Nicole Libal
Nabil J. Alkayed
Halina Offner
Publikationsdatum: 01.02.2016
Verlag: Springer US
Erschienen in: Translational Stroke Research / Ausgabe 1/2016
Print ISSN: 1868-4483
Elektronische ISSN: 1868-601X
DOI: https://doi.org/10.1007/s12975-015-0436-4

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2016

Therapy with the Combination of Amlodipine and Irbesartan Has Persistent Preventative Effects on Stroke Onset Associated with BDNF Preservation on Cerebral Vessels in Hypertensive Rats

Fluid Intake Related to Brain Edema in Acute Middle Cerebral Artery Infarction

Post-Stroke Walking Behaviors Consistent with Altered Ground Reaction Force Direction Control Advise New Approaches to Research and Therapy

Pharmacological Preventions of Brain Injury Following Experimental Germinal Matrix Hemorrhage: an Up-to-Date Review

Animal Models for the Study of Subarachnoid Hemorrhage: Are We Moving Towards Increased Standardization?